Technologies for circulating tumor cell separation from whole blood

Journal of Hematology & Oncology

Viola Nagygyörgy¹  Petra Bankó²  András Telekes³  Sun Young Lee⁴  Chang Hoon Chae⁵  Miklós Zrínyi⁵  Dong Hyu Cho⁶ 

[1] Celldi Kft;Department of Biochemical Engineering, Budapest University of Technology and Economics;Department of Oncology, St. Lazarus Hospital;Department of Radiation Oncology, Chonbuk National University Hospital;Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University;Research Institute of Clinical Medicine of Chonbuk National University-Biomedical, Research Institute of Chonbuk National University Hospital;

关键词: Cancer;    CTC;    Circulating;    Tumor cell;    Whole blood;    Separation;   

DOI  :  10.1186/s13045-019-0735-4

来源: DOAJ

【 摘 要 】

Abstract The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using technological innovations. One of the key research fields involves the separation and detection of circulating tumor cells (CTC) because of their suggested important role in early cancer diagnosis and prognosis, namely, providing easy access by a liquid biopsy from blood to identify metastatic cells before clinically detectable metastasis occurs and to study the molecular and genetic profile of these metastatic cells. Provided the opportunity to further progress the development of technology for treating cancer, several CTC technologies have been proposed in recent years by various research groups and companies. Despite their potential role in cancer healthcare, CTC methods are currently mainly used for research purposes, and only a few methods have been accepted for clinical application because of the difficulties caused by CTC heterogeneity, CTC separation from the blood, and a lack of thorough clinical validation. Therefore, the standardization and clinical application of various developed CTC technologies remain important subsequent necessary steps. Because of their suggested future clinical benefits, we focus on describing technologies using whole blood samples without any pretreatment and discuss their advantages, use, and significance. Technologies using whole blood samples utilize size-based, immunoaffinity-based, and density-based methods or combinations of these methods as well as positive and negative enrichment during separation. Although current CTC technologies have not been truly implemented yet, they possess high potential as future clinical diagnostic techniques for the individualized therapy of patients with cancer. Thus, a detailed discussion of the clinical suitability of these new advanced technologies could help prepare clinicians for the future and can be a foundation for technologies that would be used to eliminate CTCs in vivo.

【 授权许可】

Unknown